<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01482182</url>
  </required_header>
  <id_info>
    <org_study_id>2011-05-087</org_study_id>
    <nct_id>NCT01482182</nct_id>
  </id_info>
  <brief_title>Predictive Value of FDG PET/CT, DWI and DCE-MRI Scans for Non-small Cell Lung Cancer Patients Receiving Chemotherapy</brief_title>
  <official_title>Prediction of Chemotherapy Response and Patient Prognosis in Non-small Cell Lung Cancer: Dynamic Contrast-enhanced MRI and Diffusion-weighted Imaging Versus Volume-based Parameter of 18F-FDG PET</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Samsung Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Guerbet</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Samsung Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      In this prospective study, the investigators will evaluate and compare the usefulness of&#xD;
      functional and volumetric informations obtained by 18F-FDG PET and MRI before and after the&#xD;
      palliative chemotherapy with the aim of predicting tumor response and prognosis in patients&#xD;
      with advanced Non-small Cell Lung Cancer (NSCLC).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Study cohort will undergo PET/CT and MRI scans prior to chemotherapy and after the first&#xD;
      chemotherapy cycle. MRI scans include DCE-MRI and DWI. The following parameters will be&#xD;
      calculated using these values:&#xD;
&#xD;
        1. Metabolic parameters on FDG-PET A. SUV change ratio (SCR) = SUVpost/SUVpre B. MTV change&#xD;
           ratio (VCR) = MTVpost/pre C. TLG change ratio = SCR X VCR&#xD;
&#xD;
        2. Perfusion parameters on DCE-MRI A. Kep B. K-trans C. ve&#xD;
&#xD;
        3. Diffusion parameters on DWI A. Mean ADC B. fDM&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2011</start_date>
  <completion_date type="Actual">January 2014</completion_date>
  <primary_completion_date type="Actual">November 2013</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>DWI, DCE-MRI, and FDG PET as early predictor for response and prognosis</measure>
    <time_frame>one year</time_frame>
    <description>The primary endpoint of this study is the prediction of one-year overall survival by monitoring the metabolic and functional responses of the tumor following one cycle of chemotherapy.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Correlation among DWI, DCE-MRI, and FDG PET and relationship with prognosis</measure>
    <time_frame>one year</time_frame>
    <description>Correlation among metabolic response, functional response on MRI, and standard anatomic response using the RECIST criteria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correlation among DWI, DCE-MRI, and FDG PET and relationship with prognosis</measure>
    <time_frame>one year</time_frame>
    <description>(i) the correlation among metabolic response, functional response on MRI, and standard anatomic response using the RECIST criteria (ii) the correlation between functional response (metabolic and MR parameters) and progression-free survival (iii) comparison between the predictive values of FDG-PET and MRI for one-year overall survival.</description>
  </secondary_outcome>
  <enrollment type="Actual">35</enrollment>
  <condition>Non-small Cell Lung Cancer</condition>
  <eligibility>
    <study_pop>
      <textblock>
        patients with advanced NSCLC&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologically proven NSCLC&#xD;
&#xD;
          -  Newly diagnosed Stage stage IV&#xD;
&#xD;
          -  Participant is being considered for the chemotherapy with EGFR TKI as a first line&#xD;
             therapy&#xD;
&#xD;
          -  At least one measurable primary or other intrathoracic lesion &gt;= 2cm, according to&#xD;
             RECIST&#xD;
&#xD;
          -  Performance status of 0 to 2 on the ECOG scale&#xD;
&#xD;
          -  Age 18 years or older&#xD;
&#xD;
          -  Able to tolerable PET/CT and MRI imaging required by protocol&#xD;
&#xD;
          -  Able to give study-specific informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pure bronchioloalveolar cell carcinoma histology&#xD;
&#xD;
          -  Thoracic radiotherapy, lung surgery or chemotherapy within three months prior to&#xD;
             inclusion in the study&#xD;
&#xD;
          -  Poorly controlled diabetes&#xD;
&#xD;
          -  Prior malignancy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ho Yun Lee, Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Samsung Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Samsung Medical Center</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>October 2015</verification_date>
  <study_first_submitted>November 17, 2011</study_first_submitted>
  <study_first_submitted_qc>November 28, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 30, 2011</study_first_posted>
  <last_update_submitted>November 17, 2015</last_update_submitted>
  <last_update_submitted_qc>November 17, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 20, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Non-small cell lung cancer</keyword>
  <keyword>Diffusion-weighted MRI</keyword>
  <keyword>18F-FDG PET</keyword>
  <keyword>Treatment response</keyword>
  <keyword>Prognosis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

